Trial Profile
A randomized phase I/II study to assess the safety and immunogenicity of the DNA-GTU vaccine administered by two novel routes compared to placebo in HIV-infected patients on antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV DNA vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- 09 Nov 2016 Status changed from active, no longer recruiting to completed.
- 28 Jan 2016 Status changed from recruiting to active, no longer recruiting as per United Kingdom Clinical Research Network record.
- 13 Dec 2015 Accrual rate is 100% as reported by United Kingdom Clinical Research Network record.